My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
Shriram City Union Finance biggest loser on BSEs A group
Jul 07,2017

Shriram City Union Finance slipped 4.37% at Rs 2,409.95. The stock topped the losers in A group. On the BSE, 3,276 shares were traded on the counter so far as against the average daily volumes of 419 shares in the past two weeks.

Intellect Design Arena declined 4.87% at Rs 122. The stock was the second biggest loser in A group. On the BSE, 1.13 lakh shares were traded on the counter so far as against the average daily volumes of 86,000 shares in the past two weeks.

Edelweiss Financial Services fell 2.74% at Rs 193.45. The stock was the third biggest loser in A group. On the BSE, 10.34 lakh shares were traded on the counter so far as against the average daily volumes of 2.48 lakh shares in the past two weeks.

Bharti Infratel skid 2.43% at Rs 404.90. The stock was the fourth biggest loser in A group. On the BSE, 23,000 shares were traded on the counter so far as against the average daily volumes of 91,000 shares in the past two weeks.

Page Industries tumbled 1.83% at Rs 17,070. The stock was the fifth biggest loser in A group. On the BSE, 181 shares were traded on the counter so far as against the average daily volumes of 1,183 shares in the past two weeks.

Powered by Capital Market - Live News

Tea stocks sizzle on hopes of firm prices
Jul 07,2017

Assam Company (India) (up 7.54%), Jay Shree Tea & Industries (up 4.74%), Warren Tea (up 2.41%), McLeod Russel India (up 4.23%), Goodricke Group (up 3.24%), Diana Tea (up 0.67%), James Warren Tea (up 2.05%), Rossel India (up 2.76%), Dhunseri Tea & Industries (up 0.8%), Andrew Yule & Company (up 3.59%) and Tata Global Beverages (up 2.02%) edged higher.

Meanwhile, the S&P BSE Sensex was down 39.19 points, or 0.12% to 31,330.15

As per reports, initial indicators showed that average auction prices for Darjeeling tea in the first week of June rose to Rs 360.66/kg in 2017 from Rs 346.6/kg in 2016. Leaf plucking and processing activities have been suspended since the second week of June, following the political strife in the region.

A research report indicated that the current political unrest in Darjeeling is likely to impact the production and exports of the premium tea.

Powered by Capital Market - Live News

Confidence Petroleum corrects on profit booking
Jul 07,2017

Meanwhile, the S&P BSE Sensex was down 51.26 points, or 0.16% to 31,318.08.

On the BSE, 2.72 lakh shares were traded in the counter so far, compared with average daily volumes of 6.52 lakh shares in the past one quarter. The stock had hit a high of Rs 17.64 and a low of Rs 16.77 so far during the day. The stock hit a 52-week high of Rs 17.97 on 6 July 2017. The stock hit a 52-week low of Rs 4.87 on 7 July 2016.

The stock had outperformed the market over the past one month till 6 July 2017, rising 35.77% compared with 0.31% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 123.14% as against Sensexs 5.60% rise. The scrip had also outperformed the market in past one year, rising 260.20% as against Sensexs 15.32% rise.

The small-cap company has equity capital of Rs 25.88 crore. Face value per share is Re 1.

Shares of Confidence Petroleum India rose 26.89% in nine trading sessions to settle at Rs 17.65 yesterday, 6 July 2017, from its close of Rs 13.91 on 22 June 2017.

Recent rise in the stock was triggered by the company winning orders worth Rs 361.96 crore for supplying LPG cylinders. The announcement was made during trading hours on Wednesday, 5 July 2017. Shares of Confidence Petroleum India hit an upper circuit limit of 5% to settle at Rs 17.27 on 5 July 2017.

Confidence Petroleum India will supply 30,16,352 LPG cylinders. The orders have been awarded by the BPCL, HPCL and Indian Oil Corporation, with an option of order for equivalent quantity next year, the company said in a statement.

On a consolidated basis, Confidence Petroleum India reported net loss of Rs 0.10 crore in Q4 March 2017 as against net profit of Rs 0.01 crore in Q4 March 2016. Net sales rose 69.74% to Rs 157.55 crore in Q4 March 2017 over Q4 March 2016.

Confidence Petroleum India is manufacturer of liquefied petroleum gas (LPG) cylinders for domestic, as well as commercial use.

Powered by Capital Market - Live News

Glenmark Pharma gains after getting USFDA nod for generic drug
Jul 07,2017

The announcement was made before market hours today, 7 July 2017.

Meanwhile, the BSE Sensex was down 49.21 points, or 0.16%, to 31,320.13

On the BSE, 42,000 shares were traded in the counter so far, compared with average daily volumes of 1.45 lakh shares in the past one quarter. The stock had hit a high of Rs 667.65 and a low of Rs 656.55 so far during the day. The stock had hit a 52-week high of Rs 993 on 1 November 2016. The stock had hit a 52-week low of Rs 600 on 29 May 2017.

The stock had outperformed the market over the past one month till 6 July 2017, rising 1.07% compared with 0.31% rise in the Sensex. The scrip, however, underperformed the market in past one quarter, sliding 24.06% as against Sensexs 5.60% rise. The scrip had also underperformed the market in past one year, sliding 20.09% as against Sensexs 15.32% rise.

The large-cap company has equity capital of Rs 28.22 crore. Face value per share is Re 1.

Glenmark Pharmaceuticals said that Glenmark Pharmaceuticals Inc., USA was granted final approval by the United States Food & Drug Administration (USFDA) for Amlodipine and Olmesartan Medoxomil Tablets, 5 mg/20 mg, 5 mg/40 mg, 10 mg/20 mg, and 10 mg/40 mg, the generic version of Azor Tablets, 5 mg/20 mg, 5 mg/40 mg, 10 mg/20 mg, and 10 mg/40 mg, of Daiichi Sankyo, Inc.

According to IMS Health sales data for the 12 month period ended May 2017, the Azor Tablets, 5 mg/20 mg, 5 mg/40 mg, 10 mg/20 mg, and 10 mg/40 mg market achieved annual sales of approximately $211.6 million.

The companys current portfolio consists of 119 products authorized for distribution in the US marketplace and 66 ANDAs pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio, the company said.

On a consolidated basis, Glenmark Pharmaceuticals net profit rose 23.5% to Rs 183.76 crore on 10.2% rise in net sales to Rs 2424.41 crore in Q4 March 2017 over Q4 March 2016.

Glenmark Pharmaceuticals is a research-driven, global, integrated pharmaceutical organization headquartered at Mumbai, India. The company is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). It has several molecules in various stages of clinical development and is primarily focused in the areas of oncology, dermatology and respiratory.

Powered by Capital Market - Live News

Balaji Amines gains on receiving approval for expansion
Jul 07,2017

The announcement was made after market hours yesterday, 6 July 2017.

Meanwhile, the S&P BSE Sensex was down 55.63 points, or 0.18% to 31,313.71.

On the BSE, 32,000 shares were traded in the counter so far, compared with average daily volumes of 5,249 shares in the past one quarter. The stock had hit a high of Rs 382 and a low of Rs 355.60 so far during the day. The stock hit a record high of Rs 401.10 on 24 April 2017. The stock hit a 52-week low of Rs 249.20 on 14 July 2016.

The stock had outperformed the market over the past one month till 6 July 2017, rising 0.46% compared with 0.31% rise in the Sensex. The scrip had, however, underperformed the market in past one quarter, falling 8.47% as against Sensexs 5.60% rise. The scrip had outperformed the market in past one year, rising 29.68% as against Sensexs 15.32% rise.

The small-cap company has equity capital of Rs 6.48 crore. Face value per share is Rs 2.

Balaji Amines said it received approval from Ministry of Environment, Forest and Climate Change, Government of India (GoI) for expansion project, which includes Acetonitrile (ACN), Morpholine (MOR) & Di Methyl Amine Hydrochloride (DMAHCL) products. The project is situated at Solapur in Maharashtra. The approval was granted with a condition of acquiring no-objection certificate (NOC) from National Board for Wild Life for which the company has already applied to the GoI.

Balaji Amines net profit fell 23.4% to Rs 17.87 crore on 7.3% increase in net sales to Rs 193.14 crore in Q4 March 2017 over Q4 March 2016.

Balaji Amines makes methylamines, ethylamines, derivatives of specialty chemicals and natural products.

Powered by Capital Market - Live News

G M Breweries drops after poor Q1 outcome
Jul 07,2017

The result was announced after market hours yesterday, 6 July 2017.

Meanwhile, the S&P BSE Sensex was down 51.51 points or 0.16% at 31,317.83. The S&P BSE Small-Cap index was up 33.67 points or 0.21% at 15,823.34.

On BSE, so far 8,267 shares were traded in the counter as against average daily volume of 6,719 shares in the past one quarter. The stock hit a high of Rs 471.40 and a low of Rs 448.25 so far during the day. The stock had hit a 52-week high of Rs 682.55 on 5 October 2016. The stock had hit a 52-week low of Rs 394 on 30 May 2017.

The stock had outperformed the market over the past one month till 6 July 2017, rising 11.86% compared with 0.31% rise in the Sensex. The scrip, however, underperformed the market in past one quarter, rising 4.04% as against Sensexs 5.60% rise. The scrip had also underperformed the market in past one year, sliding 21.29% as against Sensexs 15.32% rise.

The small-cap company has equity capital of Rs 14.62 crore. Face value per share is Rs 10.

G M Breweries is engaged in manufacturing and marketing of country liquor.

Powered by Capital Market - Live News

Lakshmi Vilas Bank slips ex-dividend
Jul 07,2017

Meanwhile, the S&P BSE Sensex was down 43.74 points, or 0.14% to 31,325.60.

On the BSE, 60,000 shares were traded in the counter so far, compared with average daily volumes of 2.08 lakh shares in the past one quarter. The stock had hit a high of Rs 204.30 and a low of Rs 201.55 so far during the day. The stock hit a record high of Rs 209.80 on 6 July 2017. The stock hit a 52-week low of Rs 101.60 on 7 July 2016.

The stock had outperformed the market over the past one month till 6 July 2017, rising 9.67% compared with 0.31% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 22.72% as against Sensexs 5.60% rise. The scrip had also outperformed the market in past one year, rising 94.81% as against Sensexs 15.32% rise.

The mid-cap company has equity capital of Rs 191.81 crore. Face value per share is Rs 10.

Before turning ex-dividend, the stock offered a dividend yield of 1.32% based on the closing price of Rs 204.75 yesterday, 6 July 2017.

Net profit of Lakshmi Vilas Bank rose 6.30% to Rs 52.16 on 14% rise in operating income to Rs 864.99 crore in Q4 March 2017 over Q4 March 2016.

Lakshmi Vilas Bank is a full-fledged commercial bank. Its operations are spread over a network of 504 branches (plus 7 extension counters) with pan-India presence, supervised by 11 regional offices.

Powered by Capital Market - Live News

Navin Fluorine inches up after approval for sale of unit
Jul 07,2017

The announcement was made after market hours yesterday, 6 July 2017.

Meanwhile, the S&P BSE Sensex was down 36.29 points or 0.12% at 31,333.05

On BSE, so far 429 shares were traded in the counter as against average daily volume of 12,166 shares in the past one quarter. The stock hit a high of Rs 3,087 and a low of Rs 3,050.10 so far during the day. The stock had hit a 52-week high of Rs 3,250 on 5 April 2017. The stock had hit a 52-week low of Rs 1,968 on 7 July 2016.

The small-cap company has equity capital of Rs 9.85 crore. Face value per share is Rs 10.

It may be recalled that Navin Fluorine Internationals board of directors at its meeting held on 28 April 2017 decided that the facility relating to manufacture and sale of specialty fluorochemicals set up at Dahej will be transferred to the joint venture company Convergence Chemicals.

Navin Fluorine Internationals net profit fell 6.73% to Rs 29.38 crore on 5.79% rise in net sales to Rs 200.53 crore in Q4 March 2017 over Q4 March 2016.

Navin Fluorine International is the largest integrated specialty fluorochemical company in India.

Powered by Capital Market - Live News

IDFC Bank gains after clarification
Jul 07,2017

Meanwhile, the S&P BSE Sensex was down 34.94 points, or 0.11% to 31,334.40.

On the BSE, 12.45 lakh shares were traded in the counter so far, compared with average daily volumes of 12 lakh shares in the past one quarter. The stock had hit a high of Rs 66 and a low of Rs 64.50 so far during the day. The stock hit a record high of Rs 83.45 on 28 September 2016. The stock hit a 52-week low of Rs 46.30 on 7 July 2016.

The stock had outperformed the market over the past one month till 6 July 2017, rising 7.46% compared with 0.31% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 4.88% as against Sensexs 5.60% rise. The scrip had also outperformed the market in past one year, rising 33.65% as against Sensexs 15.32% rise.

The large-cap company has equity capital of Rs 3,401 crore. Face value per share is Rs 10.

Media reports suggested that Shriram Transport Finance, Shriram City Union Finance will merge with IDFC Bank; and Shriram Capitals Life, General insurance business will merge with IDFC.

IDFC Bank clarified after market hours yesterday, 6 July 2017, that it keeps evaluating opportunities from time to time and should anything concrete fructify, it will inform the exchanges as appropriate. At this point, there is nothing that can be disclosed. Under the circumstances, it is unable to confirm or deny the news reports. Meanwhile, it cannot comment on the market speculations.

Net profit of IDFC Bank rose 6.60% to Rs 175.95 crore on 16.7% rise in operating income to Rs 2279.65 crore in Q4 March 2017 over Q4 March 2016.

IDFC Bank, a subsidiary of IDFC, is a universal bank, offering financial solutions through its nationwide branches, internet and mobile.

Powered by Capital Market - Live News

Bharat Forge gains after signing pact with Israeli firm
Jul 07,2017

The announcement was made after market hours yesterday, 6 July 2017.

Meanwhile, the S&P BSE Sensex was down 45.26 points, or 0.14% to 31,324.08.

On the BSE, 19,000 shares were traded in the counter so far, compared with average daily volumes of 67,136 shares in the past one quarter. The stock had hit a high of Rs 1,130.25 and a low of Rs 1,115.05 so far during the day. The stock hit a 52-week high of Rs 1,220.45 on 8 June 2017. The stock hit a 52-week low of Rs 716.70 on 4 August 2016.

The stock had underperformed the market over the past one month till 6 July 2017, falling 8.48% compared with 0.31% rise in the Sensex. The scrip had outperformed the market in past one quarter, rising 3.83% as against Sensexs 5.60% rise. The scrip had also outperformed the market in past one year, rising 49.21% as against Sensexs 15.32% rise.

The large-cap company has equity capital of Rs 46.56 crore. Face value per share is Rs 2.

Bharat Forge announced that its subsidiary, Kalyani Strategic Systems and Israel Aerospace Industries have signed a new memorandum of understanding (MoU) addressed to expand the joint venture that the companies are establishing. The new MoU covers the establishment of a maintenance center for selected advanced air defence systems at Hyderabad in Telengana. The two companies have also agreed on expanding their joint operations for development, manufacturing and marketing of precise ammunition systems. In February 2017, Israel Aerospace Industries has inked an MoU with Kalyani Strategic Systems (KSSL) on establishing a joint venture that will develop, build, market and manufacture selected Air Defence Systems and light-weight special purpose munitions, in accordance with the Indian Governments Make in India policy.

Net profit of Bharat Forge rose 25.32% to Rs 207.50 crore on 11.31% rise in net sales to Rs 1125.66 crore in Q4 March 2017 over Q4 March 2016.

Bharat Forge is a technology driven global leader in metal forming having transcontinental presence across ten manufacturing locations, serving several sectors including automotive, power, oil and gas, construction & mining, rail, marine and aerospace.

Powered by Capital Market - Live News

Redington India spurts after huge bulk deal
Jul 06,2017

Meanwhile, the S&P BSE Sensex was up 141.49 points, or 0.45%, to 31,387.05. The S&P BSE Mid-Cap index was up 77.01 points, or 0.52%, to 14,979.

Bulk deal boosted volume on the scrip. On BSE, so far 2.17 crore shares were traded in the counter, compared with an average volume of 99,136 shares in the past one quarter. The stock hit a high of Rs 137.45 and a low of Rs 126.10 so far during the day. The stock hit a record high of Rs 155.35 on 5 June 2017. The stock hit a 52-week low of Rs 79.70 on 9 November 2016.

The stock had underperformed the market over the past one month till 5 July 2017, falling 10.28% compared with 0.18% rise in the Sensex. The scrip, however, outperformed the market in past one quarter, rising 13.24% as against Sensexs 4.40% rise. The scrip also outperformed the market in past one year, gaining 23% as against Sensexs 15.01% rise.

The mid-cap company has an equity capital of Rs 79.97 crore. Face value per share is Rs 2.

Redington Indias consolidated net profit rose 11.15% to Rs 153.32 crore on 3.07% rise in total income to Rs 10813.14 crore in Q4 March 2017 over Q4 March 2016.

Redington India is a supply chain solutions provider worldwide to leading manufacturers of information technology, telecom, lifestyle and consumer electronics products.

Powered by Capital Market - Live News

Tamilnadu Petroproducts drops after recent sharp rally
Jul 06,2017

Meanwhile, the S&P BSE Sensex was up 159.63 points, or 0.51% at 31,405.19. The S&P BSE Small-Cap index was up 122.89 points, or 0.78% at 15,863.49.

On the BSE, 1.88 lakh shares were traded on the counter so far as against the average daily volumes of 1.64 lakh shares in the past one quarter. The stock had hit a high of Rs 56.05 and a low of Rs 53.40 so far during the day. The stock had hit a 52-week high of Rs 56.05 on 5 July 2017 and a 52-week low of Rs 20.30 on 4 August 2016.

The stock had outperformed the market over the past one month till 5 July 2017, advancing 40.68% compared with the Sensexs 0.2% fall. The scrip had also outperformed the market over the past one quarter advancing 22.04% as against the Sensexs 4.24% rise. The scrip had also outperformed the market over the past one year advancing 165.09% as against the Sensexs 15.01% rise.

The small-cap company has equity capital of Rs 89.97 crore. Face value per share is Rs 10.

Shares of Tamilnadu Petroproducts had rallied 38.25% in the preceding three trading sessions to settle at Rs 56.20 yesterday, 5 July 2017, from its close of Rs 40.65 on 30 June 2017.

Tamilnadu Petroproducts reported net loss of Rs 15.15 crore in Q4 March 2017, compared with net loss of Rs 9.26 crore in Q4 March 2016. Net sales rose 91% to Rs 248.42 crore in Q4 March 2017 over Q4 March 2016.

Tamilnadu Petroproducts is engaged in the manufacturing and selling of petrochemical and chemical products, namely Linear Alkyl Benzene and Caustic Soda.

Powered by Capital Market - Live News

PNB vaults after brokerage upgrade
Jul 06,2017

Meanwhile, the S&P BSE Sensex was up 154.78 points, or 0.5%, to 31,400.34

On the BSE, so far 7.01 lakh shares were traded in the counter, compared with average daily volumes of 10.41 lakh shares in the past one quarter. The stock had hit a high of Rs 142.75 and a low of Rs 139.75 so far during the day. The stock hit a 52-week high of Rs 185.65 on 5 May 2017. The stock hit a 52-week low of Rs 112 on 29 December 2016.

The stock had underperformed the market over the past one month till 5 July 2017, falling 8.27% compared with 0.18% rise in the Sensex. The scrip had also underperformed the market in past one quarter, falling 9.39% as against Sensexs 4.40% rise. The scrip, however, outperformed the market in past one year, gaining 20.32% as against Sensexs 15.01% rise.

The large-cap state-run bank has equity capital of Rs 425.59 crore. Face value per share is Rs 2.

A foreign brokerage firm reportedly upgraded the Punjab National Bank (PNB) stock to buy from neutral citing the risk-reward ratio turning favourable and maintained its price target of Rs 180. The brokerage expects near-term provisioning to remain elevated and pressure on the banks pre-provisioning operating profit to sustain. While subsidiaries continue to accrete value, systemic loan growth remains anaemic, the brokerage firm reportedly said.

PNB reported net profit of Rs 261.90 crore in Q4 March 2017 as compared with net loss of Rs 5367.14 crore in Q4 March 2016. Total income rose 18.31% to Rs 14989.33 crore in Q4 March 2017 over Q4 March 2016.

Government of India holds 65.01% stake in PNB (as on 31 March 2017).

Powered by Capital Market - Live News

Jubilant Life gains after USFDA nod for generic drug
Jul 06,2017

The announcement was made during trading hours today, 6 July 2017.

Meanwhile, the S&P BSE Sensex was up 160.84 points, or 0.51% to 31,406.40.

On the BSE, 36,000 shares were traded in the counter so far, compared with average daily volumes of 80,604 shares in the past one quarter. The stock had hit a high of Rs 724 and a low of Rs 706 so far during the day. The stock hit a record high of Rs 879.10 on 12 April 2017. The stock hit a 52-week low of Rs 298.05 on 18 July 2016.

The stock had underperformed the market over the past one month till 5 July 2017, falling 4.53% compared with 0.18% rise in the Sensex. The scrip had also underperformed the market in past one quarter, falling 15.38% as against Sensexs 4.40% rise. The scrip had outperformed the market in past one year, rising 122.72% as against Sensexs 15.01% rise.

The large-cap company has equity capital of Rs 15.93 crore. Face value per share is Re 1.

Jubilant Life Sciences announced that Jubilant Pharma, a material wholly owned subsidiary of the company, through one of its wholly-owned subsidiaries, has received abbreviated new drug application (ANDA) final approval for Bupropion Hydrochloride extended-release tablets USP (XL), 150 mg and 300 mg, the generic version of Wellbutrin XL of Valeant, which is used for the treatment of major depressive disorder and prevention of seasonal affective disorder.

This is the fourth approval that the company has received from the US Food and Drug Administration (USFDA) during the current financial year. As on 31 March 2017, Jubilant Life Sciences had a total of 81 ANDAs for oral solids filed in the US, of which 51 have been approved.

Jubilant Life Sciences consolidated net profit spurted 1272.3% to Rs 149.03 crore on 7% growth in net sales to Rs 1565.79 crore in Q4 March 2017 over Q4 March 2016.

Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients and drug discovery solutions.

Powered by Capital Market - Live News

OM Metals gallops after sale of cineplex division
Jul 06,2017

The announcement was made after market hours yesterday, 5 July 2017.

Meanwhile, the S&P BSE Sensex was up 158.16 points or 0.51% at 31,403.72.

On the BSE, 1.16 lakh shares were traded in the counter so far as against average daily volume of 26,625 shares in the past one quarter. The stock hit a high of Rs 60.10 in intraday trade so far, which is 52-week high for the counter. The stock had hit a low of Rs 53.15 so far during the day. The stock had hit a 52-week low of Rs 38.30 on 22 March 2017.

The small-cap company has equity capital of Rs 9.63 crore. Face value per share is Re 1.

OM Metals Infraprojects said it has on 4 July 2017 sold its cineplex division, Om Cineplex Commercial Complex, for Rs 18 crore to Princess Infra and Development.

OM Metals Infraprojects net profit fell 81.47% to Rs 1.31 crore on 5.56% fall in net sales to Rs 66.20 crore in Q4 March 2017 over Q4 March 2016.

OM Metals Infraprojects has diverse business activities and interests related to hydro mechanical equipments, turn key solutions for steel fabrication, hydro power developments, real estate, entertainment centers and hotels.

Powered by Capital Market - Live News